Geranylgeranyl diphosphate synthase: an emerging therapeutic target (Q28252056)

https://api.crossref.org/works/10.1038/CLPT.2011.215

Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.215

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.215

Pleiotropic effects of statins

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.215

Rho and Rac take center stage

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.215

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.215

Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.215

Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

20 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

The intermediate enzymes of isoprenoid metabolism as anticancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Central role of peroxisomes in isoprenoid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

The SREBP pathway--insights from Insigs and insects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Antitumor effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Design, synthesis, and evaluation of sugar amino acid based inhibitors of protein prenyl transferases PFT and PGGT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

The antitumor potential of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

inferred from DOI database lookup

7 January 2021

based on heuristic

Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.215

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2011.215

1 reference

Consolidated OpenCitations Corpus – April 2017

4914121

4914121

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference